Cardiology

Dr. Granger discusses the current underuse of these agents and the steps cardiologists need to take to increase prescription rates and uptake for patients.

Dr. Pagidipati highlights her own approach to weight management, from lifestyle changes, diet, and medication to metabolic procedures.

Data from the VITAL-AF trial indicate universal screening with single-lead ECGs among patients 65 years and older in primary care settings did not significantly increase in new atrial fibrillation diagnoses, but was more effective in patients aged 85 years or older.

The University of Colorado expert joins for a 5-part interview on making sense of the boom of new agents and care strategies.

The Yale Associate Chief of Cardiovascular Medicine discusses improved use of available drug classes, as well as the potential approval for omecamtiv mecarbil.

From a couple of novel heart failure treatments to a promising dual receptor agonist, here's a rundown of expected pipeline news this year in heart disease.

Results of the VISION Cardiac Surgery study indicate measurements of hs-TnI the first day after surgery could provide insight into the risk of mortality in the first 30 days after cardiac surgery.

The Johns Hopkins expert details recent advances in remote cardiovascular care and research, and explains how the field will continue to evolve.

The absolute survival rate observed for US patients with IHCA and COVID-19 was 11.9%.

Our latest case report from Brady Pregerson, MD, features a woman in her mid-80s with a history of breast cancer presenting to the hospital with a burning sensation in her chest for the past 3 days she describes as feeling like indigestion. Can you determine the correct diagnosis?

A review of data from the prospective SmartCare-CAD trial details the primary drivers of nonparticipation in telerehabilitation programs among patients with cardiovascular conditions.

The complete response letter from the FDA cited a lack of effectiveness in slowing the loss of kidney function in patients with Alport syndrome.

The CRL for bardoxolone methyl for treatment of CKD caused by Alport syndrome comes less than 3 months after an FDA advisory committee voted unanimously against approval of Reata Pharmaceutical's once-daily, orally administered activator of Nrf2.

In this section of our Disease State Series, readers will find a list of resources curated by our editorial staff with the help of key opinion leaders to provide insight into management of heart failure for primary care providers.

Each month, our editorial staff compiles a month in review highlighting the most popular content from the past month. February's month in review features FDA approvals, heart failure trials, and data from ISC 2022.

New research suggests pregnancies conceived with assisted reproductive technology were associated with a more than doubling in risk for acute kidney injury.

A new study indicates a novel, 2-step deep learning algorithm developed using echocardiogram videos was able to identify left ventricular hypertrophy and the cause with greater accuracy than trained clinicians.

The latest case report from Brady Pregerson, MD, features a man in his mid-60’s with hypertension and diabetes presenting to the hospital for alcohol withdrawal, with reports of tachycardia and shortness of breath. Can you determine the correct diagnosis?

An expert panel discusses where bempedoic acid currently fits into the treatment of hypercholesterolemia.

What pharmacists and providers need to know to counsel patients on when discussing the use of prescription or over-the-counter fish oil supplement as treatment for dyslipidemia and hypertriglyceridemia.

Having a healthy heart is an important part of disease management for people with narcolepsy who face an increased risk of cardiovascular and metabolic comorbidities.

An analysis of data from the National Inpatient Sample suggests pregnancies conceived by assisted reproductive technology carried a 1.7- and 2.5-fold increase in risk for arrhythmia and acute kidney injury compared to those conceived without ART.

The expanded indication for the CardioMEMS HF System includes patients with NYHA Class II heart failure and elevated levels of natriuretic peptides.

With the field already booming with capability, a Penn Medicine expert discusses her team's research into finding the right tools for the right patients and clinicians.

Severe financial strain was associated with a 61% increase in 180-day mortality risk, compared to patients with no strain.

A pilot trial from Perelman showed patients were far more likely to provide blood pressure levels via text than a standard online patient portal.

More than 1-in-3 patients with T2D and ASCVD in a large cohort were receiving none of the 3 evidence-based therapies associated with significant cardiovascular benefit, including lipid-, blood pressure-, and glucose-lowering pharmacotherapy.

Higher variability of adiposity indices was associated with significantly increased risk of CVD outcomes in standard of care, but not in the intensive lifestyle intervention group.